Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

The impact of a pharmaceutical care program for patients with B-cell lymphoma treated with ibrutinib

The impact of a pharmaceutical care program for patients with B-cell lymphoma treated with ibrutinib

Posted by on Jul 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with B-cell non-Hodgkin's lymphoma (NHL). This study concluded that the management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better tolerance than...

Read More

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

Posted by on Jun 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...

Read More

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...

Read More

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Which patients with diffuse large B cell lymphoma benefit most from CAR-T treatment?

Posted by on Jun 7, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of CAR-T treatment for patients with diffuse large B cell lymphoma (DLBCL). The authors found that while a significant number of all patients benefitted from the treatment, some patients were more likely to benefit from it than others. Some background During initial treatment for DLBCL,...

Read More

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Posted by on May 31, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients.    Some background Bruton tyrosine...

Read More

How safe and effective is biological drug brentuximab vedotin combined with R-CHP chemotherapy for patients with non-Hodgkin lymphoma?

How safe and effective is biological drug brentuximab vedotin combined with R-CHP chemotherapy for patients with non-Hodgkin lymphoma?

Posted by on May 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of adding brentuximab vedotin (Adcetris) to R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) chemotherapy for patients with non-Hodgkin lymphoma (NHL). The authors concluded that the treatment was very effective and safe for patients. Some background Chemotherapy...

Read More

Which targeted therapy leads to the best quality of life for advanced FL?

Which targeted therapy leads to the best quality of life for advanced FL?

Posted by on May 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the quality of life for patients with advanced follicular lymphoma (FL) who were treated with obinutuzumab (Gazyva) and chemotherapy compared to those treated with rituximab (Rituxan) and chemotherapy. It found that both targeted antibody therapies improved quality of life for patients with advanced FL. Some background...

Read More

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Posted by on May 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...

Read More